Table 2.

Proportion of cases with pathologic features in various glomerular diseases

Diagnosis	No. of Cases	IgG Dominant	C1q ≥2+	Tubuloreticular Inclusions	Full-House Staininga	Extraglomerular Depositsb	Tissue ANA	Mesangial Deposits	Subendothelial Deposits	Subepithelial Deposits	Subendothelial and Subepithelial Deposits
Lupus nephritis	300	0.98	0.68	0.80	0.71	0.79	0.11	1.00	0.84	0.89	0.76
All nonlupus GN	560	0.47	0.12	0.04	0.1	0.07	0	0.7	0.39	0.4	0.2
Immune complex–mediated MPGN	77	0.52	0.23	0.09	0.21	0.16	0.01	0.95	0.82	0.34	0.34
Immune complex–mediated GN, NOS	36	0.69	0.22	0.22	0.36	0.25	0	0.92	0.67	0.56	0.44
Infection-related GN	47	0.09	0.02	0.02	0.02	0.04	0	1.00	0.81	0.79	0.66
Membranous glomerulopathy	100	1.00	0.05	0.07	0.11	0.06	0	0.34	0.14	1.00	0.14
PLA2R+	51	1.00	0	0	0.08	0.02	0	0.14	0.06	1.00	0.06
PLA2R–	49	1.00	0.1	0.14	0.14	0.10	0	0.55	0.22	1.00	0.22
IgA nephropathy/HSP	100	0.01	0	0	0.07	0	0	1.00	0.45	0.18	0.13
Pauci-immune GN	100	0.17	0.02	0	0.03	0	0	0.29	0.09	0.10	0.04
Anti-GBM disease	25	1.00	0.04	0	0.04	0	0	0.12	0	0.12	0
Fibrillary GN	25	1.00	0.20	0.04	0.04	0.32	0	1.00	0	0.04	0
C1q nephropathy	25	0.12	0.88	0	0.16	0.00	0	1.00	0.12	0	0
Proliferative GN with monoclonal Ig deposits	25	1.00	0.28	0	0.04	0.04	0	0.92	0.92	0.36	0.36

ANA, anti-nuclear antibody; MPGN, membranoproliferative glomerulonephritis; NOS, not otherwise specified; PLA2R, phospholipase A2 receptor; HSP, Henoch–Schönlein purpura; Anti-GBM disease, antiglomerular basement membrane disease.

^aDefined as at least trace staining for IgG, IgA, IgM, C1q, and C3 on a scale of 0–3.

^bBy immunofluorescence with at least trace intensity or electron microscopy.